Home Geriatrics Cognitive Status Doesn’t Impact Cortical Aβ, Tau in Parkinson’s

Cognitive Status Doesn’t Impact Cortical Aβ, Tau in Parkinson’s

Cortical Aβ, tau does not differ in Parkinson’s patients who are cognitively normal, with MCI

TUESDAY, Dec. 12, 2017 (HealthDay News) — Patterns of cortical β-amyloid (Aβ) and tau are not different for patients with Parkinson’s disease (PD) who are cognitively normal (PD-CN) or with mild cognitive impairment (MCI) and for healthy adults, according to a study published online Dec. 11 in JAMA Neurology.

Joseph R. Winer, from the University of California in Berkeley, and colleagues conducted a cross-sectional study involving 29 patients with PD (15 with PD-CN and 14 with PD-MCI) and 49 healthy controls to compare tau positron emission tomographic (PET) measurements.

The researchers found that six PD patients were Aβ-positive, of whom one had PD-MCI, and 23 patients were Aβ-negative. There were no significant differences in voxel-wise contrasts of whole-brain tau PET uptake between patients with PD-CN and PD-MCI, or for all patients with PD versus Aβ-negative controls. There were no differences in tau PET binding between patients with PD-MCI and PC-CN in brain regions reflecting Alzheimer’s disease Braak stages 1/2, 3/4, or 5/6, nor was there any difference from Aβ-negative healthy older adults. In Aβ-positive patients with PD there was significantly elevated tau PET binding relative to Aβ-negative patients with PD within brain regions reflecting Alzheimer’s disease Braak stage 3/4 and Braak stage 5/6.

“Age, Aβ, and tau do not differentiate patients with PD-CN and PD-MCI,” the authors write. “Cognitive deficits in people with PD without dementia do not appear to reflect measureable Alzheimer disease.”

Two authors disclosed financial ties to the pharmaceutical industry; Avid Radiopharmaceuticals enabled use of the [18F] AV-1451 tracer.

Abstract/Full Text

Copyright © 2017 HealthDay. All rights reserved.